Short- and long-term effects of dapagliflozin as an adjunct to insulin therapy in diabetic dogs: a pilot study
Authors:
- Taís Bock NogueiraTNTaís Bock Nogueira
- José Lucas Xavier LopesJLJosé Lucas Xavier Lopes
- Frederico Aécio Carvalho SoaresFSFrederico Aécio Carvalho Soares
- Denise Iparraguirre da SilvaDSDenise Iparraguirre da Silva
- Caroline Bernardo GusmãoCGCaroline Bernardo Gusmão
- Gabriela Goulart TeixeiraGTGabriela Goulart Teixeira
- Álan Gomes PöpplÁPÁlan Gomes Pöppl
Open Access
- 6 November 2026
- journal article
- research article
- Published by Springer Nature in Veterinary Research Communications
- Vol. 51 (1) , 37
Abstract
This study evaluated adjunctive dapagliflozin therapy in insulin-treated diabetic dogs to assess short- and long-term glycemic, clinical, and laboratory outcomes in dogs with naturally occurring diabetes mellitus. Six diabetic dogs received a compounded liquid oral dapagliflozin (CLODapa) formulation (0.088 ± 0.013 mg/kg once daily) in addition to ongoing insulin therapy for 100 days. We monitored continuous glucose monitoring (CGM) before and after treatment initiation, and serially assessed clinical, biochemical, and urinary parameters. Short-term dapagliflozin administration significantly reduced mean interstitial glucose, glucose nadir and peak values, and increased time within the target glucose range (60–250 mg/dL), while decreasing time above range. Glycemic variability increased, although time spent < 60 mg/dL and clinical hypoglycemia did not increase; however, CLODapa’s initial dosage was reduced in four dogs due to concerns about hypoglycemia, increased in one, and left unchanged in another. Long-term treatment was associated with reductions in fructosamine, systolic blood pressure, alanine aminotransferase, aspartate aminotransferase, alkaline phosphatase, and cholesterol concentrations. No evidence of diabetic ketoacidosis, urinary tract infection, electrolyte imbalance, or acid–base disturbance was detected. Unintentional weight loss was documented in three patients and required a ~ 25% increase in food intake. Adjunctive dapagliflozin showed promise in improving glycemic control in diabetic dogs despite posing a risk of hypoglycemia, supporting further investigation of SGLT2 inhibition in canine diabetology.Keywords
All Related Versions
Funding Information
- Universidade Federal do Rio Grande do Sul
This publication has 21 references indexed in Scilit:
- Effect of the sodium glucose transporter-2 inhibitor dapagliflozin on urine and blood biomarkers in dogs with heart diseaseJournal of Veterinary Internal Medicine, 2026
- The effect of glycemic control on diabetic cataract progression rate in dogs: A preliminary studyThe Veterinary Journal, 2025
- Pilot study on the effects of dapagliflozin on echocardiographic parameters in dogs with symptomatic myxomatous mitral valve diseaseVeterinary and Animal Science, 2025
- Long-term effects of adding an SGLT-2 inhibitor to insulin therapy in patients with type 1 diabetes. An observational study and systematic review of real-world evidenceJournal of Endocrinological Investigation, 2025
- Unmet needs in the treatment of type 1 diabetes: why is it so difficult to achieve an improvement in metabolic control?Nutrition & Diabetes, 2024
- Effect of the sodium‐glucose cotransporter‐2 inhibitor, DWP16001, as an add‐on therapy to insulin for diabetic dogs: A pilot studyVeterinary Medicine and Science, 2024
- Dapagliflozin prevents abdominal visceral and subcutaneous adipose tissue dysfunction in the insulin‐resistant canine modelObesity, 2023
- Insulin Therapy in Small Animals, Part 3: DogsVeterinary Clinics of North America: Small Animal Practice, 2023
- Long‐term field study of lispro and neutral protamine Hagedorn insulins treatment in dogs with diabetes mellitusVeterinary Medicine and Science, 2023
- Agreeing Language in Veterinary Endocrinology (ALIVE): Diabetes mellitus - a modified Delphi-method-based system to create consensus disease definitionsThe Veterinary Journal, 2022